{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:19:38Z","timestamp":1722039578214},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pbb.2024.173825","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T09:04:02Z","timestamp":1720947842000},"page":"173825","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biochemical challenges for testing novel anti-panic drugs in humans"],"prefix":"10.1016","volume":"242","author":[{"given":"Kenneth B.","family":"Abrams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel T.","family":"Folger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence J.","family":"Wichlinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2024.173825_bb0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0306-4530(96)00005-4","article-title":"Neuroendocrine responses to laboratory panic: cognitive intervention in the doxapram model","volume":"21","author":"Abelson","year":"1996","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2024.173825_bb0010","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.addbeh.2008.02.018","article-title":"Biological challenge procedures used to study co-occurring nicotine dependence and panic disorder","volume":"33","author":"Abrams","year":"2008","journal-title":"Addict. Behav."},{"key":"10.1016\/j.pbb.2024.173825_bb0015","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/da.22652","article-title":"Nicotine deprivation attenuates panic reactivity in smokers: findings from a placebo-controlled nicotine patch study","volume":"34","author":"Abrams","year":"2017","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pbb.2024.173825_bb0020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pbb.2013.02.012","article-title":"Role of TRPV1 receptors on panic-like behaviors mediated by the dorsolateral periaqueductal gray in rats","volume":"105","author":"Almeida-Santos","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173825_bb0025","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2022"},{"key":"10.1016\/j.pbb.2024.173825_bb0030","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0306-4530(01)00075-0","article-title":"Inhalation of 35% CO(2) results in activation of the HPA axis in healthy volunteers","volume":"27","author":"Argyropoulos","year":"2002","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2024.173825_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/da.20048","article-title":"Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers","volume":"21","author":"Bailey","year":"2005","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pbb.2024.173825_bb0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0269881106063889","article-title":"A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers","volume":"21","author":"Bailey","year":"2007","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.pbb.2024.173825_bb0045","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1177\/0269881111408455","article-title":"Validating the inhalation of 7.5% CO2 in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD)","volume":"25","author":"Bailey","year":"2011","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.pbb.2024.173825_bb0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-1781(88)90005-4","article-title":"Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls","volume":"23","author":"Balon","year":"1988","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0055","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00406-021-01324-1","article-title":"The German Guidelines for the treatment of anxiety disorders: first revision","volume":"272","author":"Bandelow","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pbb.2024.173825_bb0060","series-title":"Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants","author":"Barceloux","year":"2012"},{"key":"10.1016\/j.pbb.2024.173825_bb0065","series-title":"Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic","author":"Barlow","year":"2004"},{"key":"10.1016\/j.pbb.2024.173825_bb0070","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1037\/0021-843X.103.3.553","article-title":"Definitions of panic attacks and panic disorder in the DSM-IV: implications for research","volume":"103","author":"Barlow","year":"1994","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.pbb.2024.173825_bb0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbr.2017.11.002","article-title":"Effect of single doses of pindolol and d-fenfluramine on flumazenil-induced anxiety in panic disorder patients","volume":"357\u2013358","author":"Bernik","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/026988119500900101","article-title":"The effects of D-fenfluramine on mood and performance, and on neuroendocrine indicators of 5-HT function","volume":"9","author":"Bond","year":"1995","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.pbb.2024.173825_bb0085","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1177\/0269881109102541","article-title":"mCPP: an undesired addition to the ecstasy market","volume":"24","author":"Bossong","year":"2010","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.pbb.2024.173825_bb0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0278-5846(91)90086-G","article-title":"Comparison of the panicogenic effect of cholecystokinin 30-33 and carbon dioxide in panic disorder","volume":"15","author":"Bradwejn","year":"1991","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1176\/ajp.151.2.261","article-title":"Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients","volume":"151","author":"Bradwejn","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/713783681","article-title":"Cholecystokinin and panic disorder: past and future clinical research strategies","volume":"234","author":"Bradwejn","year":"2001","journal-title":"Scand. J. Clin. Lab. Investig. Suppl."},{"key":"10.1016\/j.pbb.2024.173825_bb0105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpsyc.1991.01810310021005","article-title":"Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings","volume":"48","author":"Bradwejn","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0110","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF02244846","article-title":"Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers","volume":"114","author":"Bradwejn","year":"1994","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173825_bb0115","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003495-199142060-00010","article-title":"Flumazenil","volume":"42","author":"Brogden","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.pbb.2024.173825_bb0120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.biopsych.2004.06.013","article-title":"Smoking and respiratory irregularity in panic disorder","volume":"56","author":"Caldirola","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0125","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/JEP.S261403","article-title":"Experimental drugs for panic disorder: an updated systematic review","volume":"13","author":"Caldirola","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173825_bb0130","first-page":"851","article-title":"Regional brain activation due to pharmacologically induced adrenergic interoceptive stimulation in humans","volume":"64","author":"Cameron","year":"2002","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.pbb.2024.173825_bb0135","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archpsyc.1985.01790280040004","article-title":"Noradrenergic function and the mechanism of action of antianxiety treatment: I. The effect of long-term alprazolam treatment","volume":"42","author":"Charney","year":"1985","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0447.1992.tb03266.x","article-title":"Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients","volume":"86","author":"Charney","year":"1992","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pbb.2024.173825_bb0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00006842-195111000-00001","article-title":"Life situations, emotions, and neurocirculatory asthenia (anxiety neurosis, neurasthenia, effort syndrome)","volume":"13","author":"Cohen","year":"1951","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.pbb.2024.173825_bb0150","first-page":"173","article-title":"Pharmacological probes in panic disorder","author":"Coplan","year":"1996","journal-title":"Adv. Neurobiol. Anxiety Disord. N. Y."},{"key":"10.1016\/j.pbb.2024.173825_bb0155","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0006-3223(98)00241-8","article-title":"The 35% CO2 inhalation procedure: test-retest reliability","volume":"45","author":"Coryell","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.eurpsy.2004.06.009","article-title":"The influence of ethanol infusion on the effects of 35% CO2 challenge. A study in panic disorder patients and healthy volunteers","volume":"20","author":"Cosci","year":"2005","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0006-3223(91)90069-X","article-title":"Lactate vulnerability after alprazolam versus placebo treatment of panic disorder","volume":"30","author":"Cowley","year":"1991","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0170","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/archpsyc.1989.01810060031006","article-title":"Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings","volume":"46","author":"de Montigny","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0175","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/hup.2261","article-title":"The effect of a clinically effective and non-effective dose of lorazepam on 75% CO\u2082-induced anxiety","volume":"27","author":"Diaper","year":"2012","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.pbb.2024.173825_bb0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0269881112443742","article-title":"Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic","volume":"27","author":"Diaper","year":"2013","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.pbb.2024.173825_bb0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00702-012-0811-1","article-title":"Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder","volume":"120","author":"Dresler","year":"2013","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pbb.2024.173825_bb0190","series-title":"Neurobiological Approaches to Human Disease, Neuronal Control of Bodily Function: Basic and Clinical Aspects","first-page":"379","article-title":"Interaction of expectancy and physiological stressors in a laboratory model of panic","volume":"vol. 2","author":"Ehlers","year":"1988"},{"key":"10.1016\/j.pbb.2024.173825_bb0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00213-007-0738-7","article-title":"Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study","volume":"192","author":"Eser","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173825_bb0200","series-title":"Handbook of Behavioral Neuroscience, Handbook of Anxiety and Fear","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1569-7339(07)00019-7","article-title":"Chapter 5.3 experimental models: panic and fear","author":"Esquivel","year":"2008"},{"key":"10.1016\/j.pbb.2024.173825_bb0205","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-2004-827175","article-title":"Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile","volume":"37","author":"Feuchtl","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0210","first-page":"237","article-title":"Ventilatory and circulatory effects of doxapram, mediated by carotid body chemoreceptors","volume":"17","author":"Folgering","year":"1981","journal-title":"Bull. Eur. Physiopathol. Respir."},{"key":"10.1016\/j.pbb.2024.173825_bb0215","first-page":"83","article-title":"Actions of caffeine in the brain with special reference to factors that contribute to its widespread use","volume":"51","author":"Fredholm","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2024.173825_bb0220","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biopsych.2008.12.027","article-title":"Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ","volume":"66","author":"Fujimura","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pnpbp.2012.08.008","article-title":"Effects of ADORA2A gene variation and caffeine on prepulse inhibition: a multi-level risk model of anxiety","volume":"40","author":"Gajewska","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-1781(93)90036-G","article-title":"Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder","volume":"48","author":"Goddard","year":"1993","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0235","doi-asserted-by":"crossref","DOI":"10.1007\/s40263-023-01042-3","article-title":"Effect of BI 1358894 on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety, panic symptoms, and stress biomarkers: a phase I randomized trial in healthy males","author":"Goettel","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2024.173825_bb0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/anxi.3070010108","article-title":"Consistencies between recalled panic and lactate-induced panic","volume":"1","author":"Goetz","year":"1994","journal-title":"Anxiety"},{"key":"10.1016\/j.pbb.2024.173825_bb0245","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.1983.01790090041006","article-title":"Effect of acute beta-adrenergic blockade on lactate-induced panic","volume":"40","author":"Gorman","year":"1983","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0250","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1176\/ajp.141.7.857","article-title":"Response to hyperventilation in a group of patients with panic disorder","volume":"141","author":"Gorman","year":"1984","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archpsyc.1988.01800250035006","article-title":"Ventilatory physiology of patients with panic disorder","volume":"45","author":"Gorman","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0260","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0006-3223(90)90510-9","article-title":"High-dose carbon dioxide challenge test in anxiety disorder patients","volume":"28","author":"Gorman","year":"1990","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0265","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1176\/appi.ajp.157.4.493","article-title":"Neuroanatomical hypothesis of panic disorder, revised","volume":"157","author":"Gorman","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0270","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.neubiorev.2020.09.024","article-title":"A way forward for anxiolytic drug development: testing candidate anxiolytics with anxiety-potentiated startle in healthy humans","volume":"119","author":"Grillon","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2024.173825_bb0275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0165-1781(97)00041-3","article-title":"Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls","volume":"71","author":"Gurguis","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0280","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0006-3223(93)90199-N","article-title":"Noradrenergic response to intravenous yohimbine in patients with depression and comorbidity of depression and panic","volume":"34","author":"Guthrie","year":"1993","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0285","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.psychres.2004.10.010","article-title":"Doxapram-induced panic attacks and cortisol elevation","volume":"133","author":"Gutman","year":"2005","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0290","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0010-440X(83)90059-7","article-title":"Pharmacologic models of anxiety","volume":"24","author":"Guttmacher","year":"1983","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0295","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.neubiorev.2012.09.001","article-title":"Classical and novel approaches to the preclinical testing of anxiolytics: a critical evaluation","volume":"37","author":"Haller","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2024.173825_bb0300","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0017","article-title":"How the heart speaks to the brain: neural activity during cardiorespiratory interoceptive stimulation","volume":"371","author":"Hassanpour","year":"2016","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.pbb.2024.173825_bb0305","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/BF02806003","article-title":"Effect ofd-fenfluramine on human experimental anxiety","volume":"127","author":"Hetem","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173825_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43045-023-00315-3","article-title":"Epidemiology of anxiety disorders: global burden and sociodemographic associations","volume":"30","author":"Javaid","year":"2023","journal-title":"Middle East Curr. Psychiatr."},{"key":"10.1016\/j.pbb.2024.173825_bb0315","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2165\/00003495-199549030-00002","article-title":"Panic disorder. Pathophysiology and drug treatment","volume":"49","author":"Johnson","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.pbb.2024.173825_bb0320","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.expneurol.2004.11.022","article-title":"Are tuberomammillary histaminergic neurons involved in CO2-mediated arousal?","volume":"193","author":"Johnson","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2024.173825_bb0325","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/0006-3223(91)90184-N","article-title":"m-Chlorophenylpiperazine as a probe of serotonin function","volume":"30","author":"Kahn","year":"1991","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0330","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00216062","article-title":"Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder","volume":"96","author":"Kahn","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173825_bb0335","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/10615806.2011.609587","article-title":"Avoidant coping in panic disorder: a yohimbine biological challenge study","volume":"25","author":"Kaplan","year":"2012","journal-title":"Anxiety Stress Coping"},{"key":"10.1016\/j.pbb.2024.173825_bb0340","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1601-5215.2007.00195.x","article-title":"Are we done with trazodone? The potential for damage by m-CPP \u2013 a metabolite of trazodone","volume":"19","author":"Kast","year":"2007","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.pbb.2024.173825_bb0345","first-page":"341","article-title":"Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level","volume":"29","author":"Katan","year":"2008","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.pbb.2024.173825_bb0350","doi-asserted-by":"crossref","first-page":"485","DOI":"10.31887\/DCNS.2011.13.4\/mkellner","article-title":"Experimental panic provocation in healthy man-a translational role in anti-panic drug development?","volume":"13","author":"Kellner","year":"2011","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.pbb.2024.173825_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2019.104433","article-title":"Copeptin in CCK-4-induced panic in healthy man: sexual dimorphisms in secretion pattern and panic response, but no correlation of copeptin with panic symptoms","volume":"110","author":"Kellner","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2024.173825_bb0360","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpsycho.2008.08.010","article-title":"Bolus isoproterenol infusions provide a reliable method for assessing interoceptive awareness","volume":"72","author":"Khalsa","year":"2009","journal-title":"Int. J. Psychophysiol."},{"key":"10.1016\/j.pbb.2024.173825_bb0365","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/eat.22387","article-title":"Altered interoceptive awareness in anorexia nervosa: effects of meal anticipation, consumption and bodily arousal","volume":"48","author":"Khalsa","year":"2015","journal-title":"Int. J. Eat. Disord."},{"key":"10.1016\/j.pbb.2024.173825_bb0370","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1523\/JNEUROSCI.4109-15.2016","article-title":"Panic anxiety in humans with bilateral amygdala lesions: pharmacological induction via cardiorespiratory interoceptive pathways","volume":"36","author":"Khalsa","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2024.173825_bb0375","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.psyneuen.2004.01.009","article-title":"Effects of propranolol on symptom and endocrine responses to pentagastrin","volume":"29","author":"Khan","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2024.173825_bb0380","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/archpsyc.1993.01820160076009","article-title":"False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis","volume":"50","author":"Klein","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0385","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.genhosppsych.2021.11.005","article-title":"Effects of caffeine on anxiety and panic attacks in patients with panic disorder: a systematic review and meta-analysis","volume":"74","author":"Klevebrant","year":"2022","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0390","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2005-837768","article-title":"Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges","volume":"38","author":"Kronenberg","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0395","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1176\/appi.ajp.157.5.821","article-title":"Response to flumazenil in women with premenstrual dysphoric disorder","volume":"157","author":"Le Mell\u00e9do","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0400","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-3223(93)90299-S","article-title":"Panic attacks induced by doxapram","volume":"33","author":"Lee","year":"1993","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.janxdis.2021.102429","article-title":"Practical considerations for testing the effects of cannabidiol on human anxiety","volume":"82","author":"Leen-Feldner","year":"2021","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.pbb.2024.173825_bb0410","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-022-06258-7","article-title":"A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide-enriched air breathing challenge","author":"Leen-Feldner","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173825_bb0415","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.162","article-title":"CO2 exposure as translational cross-species experimental model for panic","volume":"6","author":"Leibold","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0420","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.biopsych.2012.09.004","article-title":"Benzodiazepines counteract rostral anterior cingulate cortex activation induced by cholecystokinin-tetrapeptide in humans","volume":"73","author":"Leicht","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0425","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.55.1.136","article-title":"The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: a controlled study","volume":"55","author":"Leone","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2024.173825_bb0430","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1037\/a0029423","article-title":"The interaction of nicotine withdrawal and panic disorder in the prediction of panic-relevant responding to a biological challenge","volume":"27","author":"Leyro","year":"2013","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.pbb.2024.173825_bb0435","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00004714-198602000-00004","article-title":"Alprazolam in the treatment of panic disorders","volume":"6","author":"Liebowitz","year":"1986","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2024.173825_bb0440","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0165-1781(95)02530-A","article-title":"Effects of intravenous diazepam pretreatment on lactate-induced panic","volume":"58","author":"Liebowitz","year":"1995","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0445","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0361-9230(87)90106-7","article-title":"Bidirectional effects of chronic treatment with agonists and inverse agonists at the benzodiazepine receptor","volume":"19","author":"Little","year":"1987","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.pbb.2024.173825_bb0450","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1176\/jnp.13.1.22","article-title":"The lactic acid response to alkalosis in panic disorder","volume":"13","author":"Maddock","year":"2001","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"key":"10.1016\/j.pbb.2024.173825_bb0455","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0005-7967(86)90036-7","article-title":"Biological models of panic disorder and agoraphobia\u2014a review","volume":"24","author":"Margraf","year":"1986","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.pbb.2024.173825_bb0460","first-page":"296","article-title":"Ambulatory monitoring of respiration in anxiety","volume":"2","author":"Martinez","year":"1996","journal-title":"Anxiety"},{"key":"10.1016\/j.pbb.2024.173825_bb0465","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.psychres.2015.03.001","article-title":"Heart rate and respiratory response to doxapram in patients with panic disorder","volume":"227","author":"Martinez","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0470","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.psychres.2015.07.069","article-title":"Lack of specific association between panicogenic properties of caffeine and HPA-axis activation. A placebo-controlled study of caffeine challenge in patients with panic disorder","volume":"229","author":"Masdrakis","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0475","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00213-014-3776-y","article-title":"Women with PTSD have a changed sensitivity to GABA-A receptor active substances","volume":"233","author":"M\u00f6ller","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173825_bb0480","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/jcbfm.1985.55","article-title":"Adrenergic-induced enhancement of brain barrier system permeability to small nonelectrolytes: choroid plexus versus cerebral capillaries","volume":"5","author":"Murphy","year":"1985","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.pbb.2024.173825_bb0485","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0165-1781(00)00135-9","article-title":"Double-blind acute clonazepam vs. placebo in carbon dioxide-induced panic attacks","volume":"94","author":"Nardi","year":"2000","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0490","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/da.20354","article-title":"A caffeine challenge test in panic disorder patients, their healthy first-degree relatives, and healthy controls","volume":"25","author":"Nardi","year":"2008","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pbb.2024.173825_bb0495","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.psychres.2008.06.023","article-title":"Panic disorder and social anxiety disorder subtypes in a caffeine challenge test","volume":"169","author":"Nardi","year":"2009","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0500","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.janxdis.2007.12.002","article-title":"Use of the Panic Attack Questionnaire-IV to assess non-clinical panic attacks and limited symptom panic attacks in student and community samples","volume":"22","author":"Norton","year":"2008","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.pbb.2024.173825_bb0505","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1192\/bjp.160.2.165","article-title":"Panic attacks. A neurochemical overview of models and mechanisms","volume":"160","author":"Nutt","year":"1992","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.pbb.2024.173825_bb0510","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archpsyc.1990.01810220033004","article-title":"Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder","volume":"47","author":"Nutt","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0515","series-title":"The Effects of Single Dose Anxiolytic Medication on the CO2 Models of Anxiety: Differentiation of Subjective and Objective Measures [WWW Document]","author":"Papadopoulos","year":"2008"},{"key":"10.1016\/j.pbb.2024.173825_bb0520","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1176\/ajp.154.11.1557","article-title":"Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 Subjects","volume":"154","author":"Papp","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0525","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40501-017-0128-7","article-title":"Management of treatment-resistant panic disorder","volume":"4","author":"Perna","year":"2017","journal-title":"Curr. Treat. Options Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0530","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.jcp.0000125682.97466.3c","article-title":"Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study","volume":"24","author":"Perna","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2024.173825_bb0535","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJM196712212772502","article-title":"Lactate metabolism in anxiety neurosis","volume":"277","author":"Pitts","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2024.173825_bb0540","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/anxi.3070010204","article-title":"Lactate-induced anxiety after imipramine and diazepam treatment","volume":"1","author":"Pohl","year":"1994","journal-title":"Anxiety"},{"key":"10.1016\/j.pbb.2024.173825_bb0545","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1600-0447.1991.tb03201.x","article-title":"Attenuation of carbon dioxide-induced panic after clonazepam treatment","volume":"84","author":"Pols","year":"1991","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pbb.2024.173825_bb0550","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/0006-3223(95)00494-7","article-title":"Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients","volume":"40","author":"Pols","year":"1996","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0555","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/0269881113507641","article-title":"Anxiolytic effects of vestipitant in a sub-group of healthy volunteers known to be sensitive to CO2 challenge","volume":"28","author":"Poma","year":"2014","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.pbb.2024.173825_bb0560","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neubiorev.2014.03.025","article-title":"Lifelong opioidergic vulnerability through early life separation: a recent extension of the false suffocation alarm theory of panic disorder","volume":"46","author":"Preter","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2024.173825_bb0565","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1017\/S0033291710000838","article-title":"Controlled cross-over study in normal subjects of naloxone-preceding-lactate infusions; respiratory and subjective responses: relationship to endogenous opioid system, suffocation false alarm theory and childhood parental loss","volume":"41","author":"Preter","year":"2011","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pbb.2024.173825_bb0570","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41398-018-0238-z","article-title":"The role of acid-sensitive ion channels in panic disorder: a systematic review of animal studies and meta-analysis of human studies","volume":"8","author":"Quagliato","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0887-6185(02)00181-0","article-title":"Carbon dioxide in the study of panic disorder: issues of definition, methodology, and outcome","volume":"17","author":"Rassovsky","year":"2003","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.pbb.2024.173825_bb0580","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0887-6185(02)00245-1","article-title":"CO2 hypersensitivity in recently abstinent alcohol dependent individuals","volume":"18","author":"Rassovsky","year":"2004","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.pbb.2024.173825_bb0585","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/imj.1967.16.1.20","article-title":"A clinical method for assessing the ventilatory response to carbon dioxide","volume":"16","author":"Read","year":"1967","journal-title":"Australas. Ann. Med."},{"key":"10.1016\/j.pbb.2024.173825_bb0590","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1176\/ajp.138.5.676","article-title":"Blockade by imipramine or desipramine of panic induced by sodium lactate","volume":"138","author":"Rifkin","year":"1981","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0595","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.biopsycho.2017.01.014","article-title":"Temporal stability of multiple response systems to 7.5% carbon dioxide challenge","volume":"124","author":"Roberson-Nay","year":"2017","journal-title":"Biol. Psychol."},{"key":"10.1016\/j.pbb.2024.173825_bb0600","article-title":"Assessing vulnerability to panic: a systematic review of psychological and physiological responses to biological challenges as prospective predictors of panic attacks and panic disorder","volume":"32","author":"Robinaugh","year":"2019","journal-title":"Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0605","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0165-1781(98)00066-3","article-title":"Autonomic instability during relaxation in panic disorder","volume":"80","author":"Roth","year":"1998","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0610","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bph.14578","article-title":"Treasure troves of pharmacological tools to study transient receptor potential canonical 1\/4\/5 channels","volume":"176","author":"Rubaiy","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173825_bb0615","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41398-020-00937-9","article-title":"Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans","volume":"10","author":"Salvadore","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0620","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0005-7967(88)90086-1","article-title":"Panic induction via inhalation of 5.5% CO\u2082 enriched air: a single subject analysis of psychological and physiological effects","volume":"26","author":"Sanderson","year":"1989","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.pbb.2024.173825_bb0625","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1176\/ajp.151.8.1220","article-title":"Alprazolam blockade of CO\u2082-provoked panic in patients with panic disorder","volume":"151","author":"Sanderson","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0630","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0140-6736(91)90799-U","article-title":"Feasibility of reversing benzodiazepine tolerance with flumazenil","volume":"337","author":"Savic","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2024.173825_bb0635","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.0924-2708.2004.0084.x","article-title":"Symptom profiles of natural and laboratory panic attacks","volume":"16","author":"Schruers","year":"2004","journal-title":"Acta. Neuropsychiatrica"},{"key":"10.1016\/j.pbb.2024.173825_bb0640","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0269881110367449","article-title":"One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI","volume":"25","author":"Schunck","year":"2011","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.pbb.2024.173825_bb0645","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0165-1781(94)90051-5","article-title":"Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine","volume":"53","author":"Sevy","year":"1994","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0650","first-page":"332","article-title":"Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder","volume":"22","author":"Shlik","year":"1997","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.pbb.2024.173825_bb0655","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157015907780077114","article-title":"Modelling anxiety in humans for drug development","volume":"5","author":"Siepmann","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2024.173825_bb0660","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.psychres.2004.11.011","article-title":"Physiological and behavioral effects of naloxone and lactate in normal volunteers with relevance to the pathophysiology of panic disorder","volume":"149","author":"Sinha","year":"2007","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0665","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/ajp.152.8.1168","article-title":"Irregular breathing during sleep in patients with panic disorder","volume":"152","author":"Stein","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0670","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0006-3223(98)00295-9","article-title":"Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder","volume":"45","author":"Str\u00f6hle","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0675","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0165-1781(89)90210-2","article-title":"Fenfluramine provocation of anxiety in patients with panic disorder","volume":"28","author":"Targum","year":"1989","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173825_bb0680","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.euroneuro.2012.08.011","article-title":"The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers","volume":"23","author":"T\u00f5ru","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2024.173825_bb0685","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/a-1589-6049","article-title":"Comparison of sodium lactate infusion and carbon dioxide inhalation panic provocation tests: a meta-analysis","volume":"55","author":"Tural","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0690","series-title":"Neurobiology of Panic Disorder, Frontiers of Clinical Neuroscience","first-page":"365","article-title":"Caffeine provocation of panic: a focus on biological mechanisms","author":"Uhde","year":"1990"},{"issue":"3","key":"10.1016\/j.pbb.2024.173825_bb0695","first-page":"426","article-title":"Caffeine: relationship to human anxiety, plasma MHPG and cortisol","volume":"20","author":"Uhde","year":"1984","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.pbb.2024.173825_bb0700","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1017\/S1461145706007358","article-title":"C0\u2082 challenge induced HPA axis activation in panic","volume":"10","author":"van Duinen","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2024.173825_bb0705","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0924-977X(96)00018-1","article-title":"The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder","volume":"6","author":"van Megen","year":"1996","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2024.173825_bb0710","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002130050201","article-title":"Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks","volume":"129","author":"van Megen","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173825_bb0715","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.67","article-title":"Acid\u2013base dysregulation and chemosensory mechanisms in panic disorder: a translational update","volume":"5","author":"Vollmer","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0720","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.neubiorev.2005.05.008","article-title":"Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats","volume":"29","author":"Wang","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2024.173825_bb0725","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1152\/jn.00025.2011","article-title":"Cholecystokinin facilitates neuronal excitability in the entorhinal cortex via activation of TRPC-like channels","volume":"106","author":"Wang","year":"2011","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.pbb.2024.173825_bb0730","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0006-3223(00)01000-3","article-title":"Physiologic instability in panic disorder and generalized anxiety disorder","volume":"49","author":"Wilhelm","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173825_bb0735","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2174\/1871527314666150430163142","article-title":"Laboratory, clinical and therapeutic features of respiratory panic disorder subtype","volume":"14","author":"Zugliani","year":"2015","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.pbb.2024.173825_bb0740","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0893-133X(01)00266-4","article-title":"Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers","volume":"25","author":"Zwanzger","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2024.173825_bb0745","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-0029-1241798","article-title":"Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder","volume":"42","author":"Zwanzger","year":"2009","journal-title":"Pharmacopsychiatry"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305724001199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305724001199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T17:17:28Z","timestamp":1722014248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305724001199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":149,"alternative-id":["S0091305724001199"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2024.173825","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemical challenges for testing novel anti-panic drugs in humans","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2024.173825","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"173825"}}